Day: September 14, 2024

— Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort — — No New Safety Signals or Added Systemic Safety Concerns Observed — — Data Presented at the European Society for Medical Oncology (ESMO) Congress — NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines, announced promising data from the Phase 2 basket trial of IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, in combination with Merck’s (known as MSD outside of the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) (IOB-022/KN-D38)...

– Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose– >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy– Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations– GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting– iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET WATERTOWN, Mass. and GOSSELIES, Belgium, Sept. 14, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics...

VANCOUVER, British Columbia, Sept. 13, 2024 (GLOBE NEWSWIRE) — Eco Oro Minerals Corp. (CSE:EOM) (the “Company”) announced today that Paul Robertson has resigned as Chief Executive Officer of the Company. Eric Tsung, the current Chief Financial Officer of the Company, will assume the role of Chief Executive Officer with immediate effect. Eric will continue in the role of Chief Financial Officer, a position he had held since August 3, 2017. The Company also announced today that Pierre Amariglio has tendered his resignation as member of the Company’s board of directors. Company Profile Eco Oro Minerals Corp. is a publicly-traded company and its arbitration against the Republic of Colombia is its core focus. SOURCE Eco Oro Minerals Corp. For further information: Eco Oro Minerals Corp.Tel: +1 604 682 8212, TF: +1 855 682 8212.

CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) — Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE)(TSX:GTE)(LSE:GTE) today announced that it has priced its offering of an additional $150 million aggregate principal amount of its previously issued 9.500% Senior Secured Amortizing Notes due 2029 (the “Notes”) in a private placement to persons reasonably believed to be qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), to non-U.S. persons in transactions outside the United States pursuant to Regulation S under the Securities Act, and pursuant to certain prospectus exemptions in Canada. Gran Tierra previously had outstanding US$587,590,000 aggregate principal amount of 9.500% Senior Secured Amortizing Notes due...